CLN-081, CLN-081
CLN-081-001
Phase 2 small_molecule active
Quick answer
CLN-081, CLN-081 for Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations is a Phase 2 program (small_molecule) at Cullinan Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cullinan Therapeutics
- Indication
- Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active